4.7 Article

Azole Resistance in Aspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles?

期刊

CLINICAL INFECTIOUS DISEASES
卷 62, 期 3, 页码 362-368

出版社

OXFORD UNIV PRESS INC
DOI: 10.1093/cid/civ885

关键词

emergence of azole resistance; azole fungicides; aspergilloma; invasive aspergillosis; chronic pulmonary aspergillosis

资金

  1. Astellas
  2. Basilea
  3. F2G
  4. Gilead Sciences
  5. Merck
  6. Pfizer
  7. United Medical

向作者/读者索取更多资源

Azole resistance in Aspergillus fumigatus has emerged as a global health problem. Although the number of cases of azole-resistant aspergillosis is still limited, resistance mechanisms continue to emerge, thereby threatening the role of the azole class in the management of diseases caused by Aspergillus. The majority of cases of azole-resistant disease are due to resistant A. fumigatus originating from the environment. Patient management is difficult due to the absence of patient risk factors, delayed diagnosis, and limited treatment options, resulting in poor treatment outcome. International and collaborative efforts are required to understand how resistance develops in the environment to allow effective measures to be implemented aimed at retaining the use of azoles both for food production and human medicine.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据